Gene · 90
Papers2,859
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 2,859
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-scale systems toxicology defines a KLF5-centered adverse outcome pathway linking DEHP exposure to pancreatic cancer progression and signaling programs relevant to therapy tolerance. | Front Cell Dev Biol | 2026 | 41727317 | PubTator, text mining | PubMed |
| Global Proteomic Analysis of Colorectal Cancers Stratified by Microsatellite Instability Subtype Reveals Protein Differences. | bioRxiv | 2026 | 41727057 | PubTator, text mining | PubMed |
| A closed-loop cell therapy engineered to autonomously secrete Activin A inhibitor protects from fibrodysplasia ossificans progressiva. | bioRxiv | 2026 | 41726952 | PubTator, text mining | PubMed |
| Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison. | Ann Hematol | 2026 | 41721879 | PubTator, text mining | PubMed |
| Cone-beam CT-based age-specific risk prediction model for maxillary anterior supernumerary teeth. | Sci Rep | 2026 | 41691021 | PubTator, text mining | PubMed |
| Fyn-Saracatinib Complex Structure Reveals an Active State-like Conformation. | Int J Mol Sci | 2026 | 41683573 | PubTator, text mining | PubMed |
| Comparative analysis of BMP signaling in human ECFCs reveals vascular bed-dependent ALK2 expression. | Vasc Biol | 2026 | 41603470 | PubTator, text mining | PubMed |
| Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. | Nat Commun | 2026 | 41593097 | PubTator, text mining | PubMed |
| First-In-Human Study to Assess the Pharmacokinetics and Safety of DS-6016a After Single Subcutaneous Injection in Healthy Japanese Adults. | Clin Pharmacol Drug Dev | 2026 | 41562506 | PubTator, text mining | PubMed |
| Progressive ossification in an adolescent with fibrodysplasia ossificans progressiva. | BMJ Case Rep | 2026 | 41526070 | PubTator, text mining | PubMed |
| Improved protein binder design using β-pairing targeted RFdiffusion. | Nat Commun | 2026 | 41519838 | PubTator, text mining | PubMed |
| Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib. | Br J Clin Pharmacol | 2026 | 41360500 | PubTator, text mining | PubMed |
| Protumor Macrophage Polarization Mediated by BMP2/4-ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation. | Cancer Res | 2026 | 41248425 | PubTator, text mining | PubMed |
| Evaluation of clinical cardiac safety of zilurgisertib, an activin receptor-like kinase-2 (ALK2) inhibitor, in healthy participants. | Clin Pharmacol Drug Dev | 2026 | 41127889 | PubTator, text mining | PubMed |
| Population Pharmacokinetics and Exposure-Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis. | Clin Pharmacol Ther | 2026 | 41055137 | PubTator, text mining | PubMed |
| Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study. | Eur J Haematol | 2026 | 40955124 | PubTator, text mining | PubMed |
| Fibrodysplasia ossificans progressiva: genetic and clinical characterization in a cohort of Polish patients and review of potential therapies. | J Appl Genet | 2026 | 40220125 | PubTator, text mining | PubMed |
| ACVR mutation [NM_001105.4:c.774G>T (p.Arg258Ser)] in pediatric fibrodysplasia ossificans progressiva complicated by scoliosis: a case report. | Front Pediatr | 2025 | 41473913 | PubTator, text mining | PubMed |
| Compound KTI-2338 Inhibits ACVR1 Receptor Signaling in Fibrodysplasia Ossificans Progressiva. | Pharmaceutics | 2025 | 41471105 | PubTator, text mining | PubMed |
| Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma. | Lung Cancer | 2025 | 41043322 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/90/papers?page=3